Article

July 10, 2012

Robert Margolis, MD, Addresses Incentives for Population-Based Healthcare

Robert Margolis, MD, Managing Partner and CEO, HealthCare Partners, says there needs to be a movement toward managing patients based on population.

Robert Margolis, MD, Managing Partner and CEO, HealthCare Partners, says there needs to be a movement toward managing patients based on population. The adoption of electronic health records (EHRs), predictive modeling, and telemedicine will all assist in moving toward population health.

This video interview was performed on June 21, 2012, at the America's Health Insurance Plans Institute 2012 in Salt Lake City, UT.

Related Videos

Sarah Anderson, oncology strategy lead director, Novotech

Gladys Antelo-Allen

Jonathan Eisengart, MD

Chelsee Jensen, PharmD, BCPS.

Jonathan Eisengart, MD

Sarah Anderson, oncology strategy lead director, Novotech

Jonathan Eisengart

Related Content

Oscar B. Lahoud, MD, and Kasey Bond, MPH

February 4th 2025

Addressing Cancer Care Barriers Through Community Outreach and Support

Maggie L. Shaw Oscar B. Lahoud, MD Kasey Bond, MPH

February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you are located in and with whom you work to optimize cancer-related outcomes.

February 4th 2025

Politics vs Science: The Future of US Public Health

Maggie L. Shaw Perry N. Halkitis, PhD, MS, MPH

On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.

Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine

January 29th 2025

How FcRn Blockade Targets Myasthenia Gravis Autoantibodies

Maggie L. Shaw Katie Abouzahr, MD

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.

January 28th 2025

The Evolving Annual Wellness Visit

Laura Joszt, MA Christopher Wheelock, MD

The annual wellness visit is beneficial for patients, providers, and payers with an emphasis on preventive care for early intervention.

Kirollos Hanna, PharmD

January 28th 2025

Balancing Longevity, Quality, and Cost in Oncology Care

Kyle Munz Kirollos Hanna, PharmD

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.

Aerial View of Downtown Dallas - Nate Hovee - stock.adobe.com

January 27th 2025

Balancing Innovation and Equity in Oncology Value-Based Care: Panel Discussions

Giuliana Grossi

Discussions also delved into the complexities of value-based oncology care, the growing role of real-world data, and strategies to improve access to care in hematology. Across all sessions, a common theme emerged: the need to balance innovation with patient-centered, equitable, and sustainable care models.

Related Content

Oscar B. Lahoud, MD, and Kasey Bond, MPH

February 4th 2025

Addressing Cancer Care Barriers Through Community Outreach and Support

Maggie L. Shaw Oscar B. Lahoud, MD Kasey Bond, MPH

February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you are located in and with whom you work to optimize cancer-related outcomes.

February 4th 2025

Politics vs Science: The Future of US Public Health

Maggie L. Shaw Perry N. Halkitis, PhD, MS, MPH

On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.

Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine

January 29th 2025

How FcRn Blockade Targets Myasthenia Gravis Autoantibodies

Maggie L. Shaw Katie Abouzahr, MD

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.

January 28th 2025

The Evolving Annual Wellness Visit

Laura Joszt, MA Christopher Wheelock, MD

The annual wellness visit is beneficial for patients, providers, and payers with an emphasis on preventive care for early intervention.

Kirollos Hanna, PharmD

January 28th 2025

Balancing Longevity, Quality, and Cost in Oncology Care

Kyle Munz Kirollos Hanna, PharmD

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.

Aerial View of Downtown Dallas - Nate Hovee - stock.adobe.com

January 27th 2025

Balancing Innovation and Equity in Oncology Value-Based Care: Panel Discussions

Giuliana Grossi

Discussions also delved into the complexities of value-based oncology care, the growing role of real-world data, and strategies to improve access to care in hematology. Across all sessions, a common theme emerged: the need to balance innovation with patient-centered, equitable, and sustainable care models.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions